MANNKIND CORP Depreciation
MANNKIND CORP (MNKD) reported Depreciation of $2.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- MANNKIND CORP depreciation for the quarter ending 2026-06-30 was $2.03M, a 0.39% decline year-over-year.
- MANNKIND CORP depreciation for the quarter ending 2026-03-31 was $2.02M, a 2.09% decline year-over-year.
- MANNKIND CORP depreciation for the quarter ending 2025-12-31 was $1.99M, a 7.31% decline year-over-year.
- MANNKIND CORP depreciation for the quarter ending 2025-09-30 was $2.01M, a 4.14% decline year-over-year.
- MANNKIND CORP depreciation for fiscal 2025 was $8.10M, a 10.96% increase from fiscal 2024.
- MANNKIND CORP depreciation for fiscal 2024 was $7.30M, a 62.22% increase from fiscal 2023.
- MANNKIND CORP depreciation for fiscal 2023 was $4.50M, a 36.36% increase from fiscal 2022.
- MANNKIND CORP depreciation for fiscal 2022 was $3.30M, a 65.00% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.03M 10-Q · filed 2026-08-05 | $4.05M 10-Q · filed 2026-08-05 | $6.04M derived: sum of 3 quarters · filed 2026-08-05 | $8.05M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $2.02M 10-Q · filed 2026-05-06 | $4.01M derived: sum of 2 quarters · filed 2026-05-06 | $6.02M derived: sum of 3 quarters · filed 2026-05-06 | $8.06M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.00M derived: sum of 2 quarters · filed 2026-02-26 | $6.04M derived: sum of 3 quarters · filed 2026-08-05 | $8.10M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $2.01M 10-Q · filed 2025-11-05 | $4.05M derived: sum of 2 quarters · filed 2026-08-05 | $6.11M 10-Q · filed 2025-11-05 | $8.26M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $2.04M 10-Q · filed 2026-08-05 | $4.10M 10-Q · filed 2026-08-05 | $6.25M derived: sum of 3 quarters · filed 2026-08-05 | $8.35M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.06M 10-Q · filed 2026-05-06 | $4.21M derived: sum of 2 quarters · filed 2026-05-06 | $6.31M derived: sum of 3 quarters · filed 2026-05-06 | $8.02M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.25M derived: sum of 2 quarters · filed 2026-02-26 | $5.96M derived: sum of 3 quarters · filed 2026-02-26 | $7.30M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.10M 10-Q · filed 2025-11-05 | $3.81M derived: sum of 2 quarters · filed 2025-11-05 | $5.15M 10-Q · filed 2025-11-05 | $6.40M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $1.71M 10-Q · filed 2025-08-06 | $3.05M 10-Q · filed 2025-08-06 | $4.30M derived: sum of 3 quarters · filed 2026-02-26 | $5.42M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $1.34M 10-Q · filed 2025-05-08 | $2.59M derived: sum of 2 quarters · filed 2026-02-26 | $3.71M derived: sum of 3 quarters · filed 2026-02-26 | $4.80M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.37M derived: sum of 2 quarters · filed 2026-02-26 | $3.46M derived: sum of 3 quarters · filed 2026-02-26 | $4.50M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $1.12M 10-Q · filed 2024-11-07 | $2.21M derived: sum of 2 quarters · filed 2024-11-07 | $3.25M 10-Q · filed 2024-11-07 | $4.27M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $1.09M 10-Q · filed 2024-08-07 | $2.13M 10-Q · filed 2024-08-07 | $3.15M derived: sum of 3 quarters · filed 2025-02-26 | $4.11M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $1.04M 10-Q · filed 2024-05-08 | $2.06M derived: sum of 2 quarters · filed 2025-02-26 | $3.01M derived: sum of 3 quarters · filed 2025-02-26 | $3.74M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.97M derived: sum of 2 quarters · filed 2025-02-26 | $2.70M derived: sum of 3 quarters · filed 2025-02-26 | $3.30M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $952.00K 10-Q · filed 2023-11-07 | $1.68M derived: sum of 2 quarters · filed 2023-11-07 | $2.28M 10-Q · filed 2023-11-07 | $2.83M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $727.00K 10-Q · filed 2023-08-07 | $1.33M 10-Q · filed 2023-08-07 | $1.88M derived: sum of 3 quarters · filed 2024-02-27 | $2.38M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $599.00K 10-Q · filed 2023-05-09 | $1.15M derived: sum of 2 quarters · filed 2024-02-27 | $1.66M derived: sum of 3 quarters · filed 2024-02-27 | $2.14M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $551.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.06M derived: sum of 2 quarters · filed 2024-02-27 | $1.54M derived: sum of 3 quarters · filed 2024-02-27 | $2.00M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $508.00K 10-Q · filed 2022-11-08 | $989.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.45M 10-Q · filed 2022-11-08 | $1.90M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $481.00K 10-Q · filed 2022-08-09 | $941.00K 10-Q · filed 2022-08-09 | $1.40M derived: sum of 3 quarters · filed 2023-02-23 | $1.84M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $460.00K 10-Q · filed 2022-05-05 | $914.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.36M derived: sum of 3 quarters · filed 2023-02-23 | $1.81M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $899.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.35M derived: sum of 3 quarters · filed 2023-02-23 | $1.80M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $445.00K 10-Q · filed 2021-11-09 | $455.00K 10-Q · filed 2020-11-04 | $893.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.35M 10-Q · filed 2021-11-09 | $1.80M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $448.00K 10-Q · filed 2021-08-11 | $891.00K 10-Q · filed 2021-08-11 | $1.36M derived: sum of 3 quarters · filed 2021-08-11 | $1.75M derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $443.00K 10-Q · filed 2021-05-12 | $908.00K derived: sum of 2 quarters · filed 2021-05-12 | $1.30M derived: sum of 3 quarters · filed 2021-05-12 | $1.68M derived: sum of 4 quarters · filed 2021-05-12 | |
| 2019-12-31 | $465.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $861.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.23M derived: sum of 3 quarters · filed 2021-02-25 | $1.60M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $396.00K 10-Q · filed 2020-11-04 | $767.00K derived: sum of 2 quarters · filed 2020-11-04 | $1.14M 10-Q · filed 2020-11-04 | $1.54M derived: sum of 4 quarters · filed 2020-11-04 | |
| 2019-06-30 | $371.00K 10-Q · filed 2020-08-05 | $739.00K 10-Q · filed 2020-08-05 | $1.15M derived: sum of 3 quarters · filed 2020-08-05 | $1.55M derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-03-31 | $367.00K 10-Q · filed 2020-05-06 | $400.00K 10-Q · filed 2019-05-07 | $778.00K derived: sum of 2 quarters · filed 2020-05-06 | $1.18M derived: sum of 3 quarters · filed 2020-05-06 | $1.63M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $815.00K derived: sum of 2 quarters · filed 2020-02-25 | $1.26M derived: sum of 3 quarters · filed 2020-02-25 | $1.70M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $404.00K 10-Q · filed 2019-11-08 | $849.00K derived: sum of 2 quarters · filed 2019-11-08 | $1.29M 10-Q · filed 2019-11-08 | $1.70M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2018-06-30 | $445.00K 10-Q · filed 2019-08-07 | $886.00K 10-Q · filed 2019-08-07 | $1.29M derived: sum of 3 quarters · filed 2019-08-07 | $1.75M derived: sum of 4 quarters · filed 2019-08-07 | |
| 2018-03-31 | $400.00K 10-Q · filed 2019-05-07 | $441.00K 10-Q · filed 2018-05-09 | $850.00K derived: sum of 2 quarters · filed 2019-05-07 | $1.30M derived: sum of 3 quarters · filed 2019-05-07 | $1.75M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $904.00K derived: sum of 2 quarters · filed 2019-02-26 | $1.35M derived: sum of 3 quarters · filed 2019-02-26 | $1.80M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $454.00K 10-Q · filed 2018-11-01 | $904.00K derived: sum of 2 quarters · filed 2018-11-01 | $1.35M 10-Q · filed 2018-11-01 | $1.98M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | $450.00K 10-Q · filed 2018-08-02 | $896.00K 10-Q · filed 2018-08-02 | $1.52M derived: sum of 3 quarters · filed 2019-02-26 | $2.12M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | $446.00K 10-Q · filed 2018-05-09 | $1.07M derived: sum of 2 quarters · filed 2019-02-26 | $1.67M derived: sum of 3 quarters · filed 2019-02-26 | $2.26M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | $625.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $1.22M derived: sum of 2 quarters · filed 2019-02-26 | $1.81M derived: sum of 3 quarters · filed 2019-02-26 | $2.40M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $597.00K 10-Q · filed 2017-11-07 | $1.19M derived: sum of 2 quarters · filed 2017-11-07 | $1.77M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $589.00K 10-Q · filed 2017-08-07 | $1.18M 10-Q · filed 2017-08-07 | |||
| 2015-09-30 | $3.17M 10-Q · filed 2016-11-09 | $8.28M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |